What is Dasiglucagon?
Dasiglucagon (brand name ZEGALOGUE, development code ZP-GA-1) is a synthetic stable glucagon analogue developed by Zealand Pharma. Approved by the FDA on March 22, 2021, it is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and older.
Dasiglucagon's defining feature is its stability in aqueous solution — unlike native glucagon, which must be reconstituted from a powder immediately before use, dasiglucagon is supplied as a ready-to-use autoinjector or prefilled syringe. This dramatically simplifies emergency administration during severe hypoglycemic events.
Structure
Dasiglucagon is a 29-amino-acid analogue of native human glucagon with seven amino acid substitutions designed to:
- Prevent the aspartic acid → isoaspartic acid isomerization that destabilizes native glucagon
- Block the methionine oxidation that contributes to native glucagon degradation
- Prevent fibrillation during prolonged storage in solution
- Maintain glucagon receptor (GCGR) potency equivalent to native glucagon
The result is a peptide stable in aqueous solution for over 2 years, allowing pre-filled autoinjector formulation.
Mechanism of Action
Like native glucagon, dasiglucagon:
- Activates the glucagon receptor (GCGR) on hepatocytes
- Stimulates glycogenolysis and gluconeogenesis, raising plasma glucose
- Provides emergency rescue from severe hypoglycemia (loss of consciousness, seizure, inability to swallow)
The pharmacology is identical to native glucagon for emergency rescue purposes; the innovation is in the delivery formulation, not the mechanism.
Clinical Evidence
Phase 3 (Diabetes Care 2021):
- 170 adults with T1D randomized to dasiglucagon SC vs placebo during induced hypoglycemia
- Median time to plasma glucose recovery: 10 minutes vs 40 minutes placebo (p<0.001)
- Onset comparable to reconstituted IM glucagon
Pediatric studies (ages 6-17) demonstrated equivalent efficacy and safety.
Approval History
- March 22, 2021 — FDA approval for severe hypoglycemia ages ≥6
- 2021 — EMA approval
Place in Therapy
Dasiglucagon competes in the rescue glucagon market with:
- Baqsimi (intranasal nasal-spray glucagon, Eli Lilly, FDA 2019)
- Gvoke (ready-to-use stable native glucagon autoinjector, Xeris, FDA 2019)
- GlucaGen (older lyophilized glucagon requiring reconstitution)
The market shift from lyophilized to ready-to-use rescue glucagon has dramatically improved usability for caregivers and EMS personnel during real-world hypoglycemic emergencies.
Safety Profile
Adverse events:
- Nausea, vomiting (common, expected from glucagon pharmacology)
- Headache, injection-site reactions
- Mild rebound hyperglycemia
- Rare necrolytic migratory erythema with chronic use (not relevant for emergency rescue)